Media Coverage

UCLA Health Continues to Transform Cancer Care

As we celebrate the 100-year milestone of UCLA, we'd like to acknowledge the contributions of UCLA Health Jonsson Comprehensive Cancer Center. Since its inception, the center has dedicated itself to providing the best in leading-edge and traditional cancer treatments and expertly guiding the next generation of medical research. Transformative research work from the IUO co-Director Arie Belldegrun and IUO Board Member Dennis Slamon was highlighted.  UCLA Magazine >

Transforming Cancer Care
  • Arie Belldegrun, MD developed the first FDA approved CAR-T cell therapy.
  • Dennis Slamon, MD, PhD (pictured right) led to the development of a breast cancer drug that has saved thousands of women's lives.

May 20, 2024
What does the US FDA approval of Anktiva signify for bladder cancer care?Dr. Karim Chamie,  associate professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to Oncology Central


May 14, 2024
OncLive’s April roundup of key FDA decisions in oncology – Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to OncLive.


May 3, 2024
Dr. John Lee receives grants from Department of DefenseDr. John Lee, associate professor at the UCLA David Geffen School of Medicine at UCLA, receives grants from Department of Defense. Learn more at the UCLA Health Newsroom


April 19, 2024 
Salvage RT after prostatectomy prevails in long-term comparison with adjuvant RT Dr. Amar Kishan, assistant professor and chief of genitourinary oncology service at the David Geffen School of Medicine at UCLA, provides expert commentary to MedPageToday.


April 1, 2024
Cancer researcher elected to American Society for Clinical Investigation - Dr. John Lee, associate assistant professor in residence of hematology/oncology in the David Geffen School of Medicine at UCLA, has been elected as a member of the American Society for Clinical Investigation, one of the oldest and most esteemed nonprofit honor societies of physician-scientists. Learn more at the UCLA Health Newsroom


March 27, 2024
SIR 2024: Study finds ultrasound ablation to be a precise, effective treatment for prostate cancer - Coverage of study led by Dr. Steven Raman, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA and member, UCLA Health Jonsson Comprehensive Cancer Center at Health Imagine News

Additional Coverage: Yahoo! NewsNewsmaxMedicineNetHealth Day, United Press International, eCancer, Easy Health Options


March 18, 2024
Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary studyDr. Amar Kishan, assistant professor and chief of genitourinary oncology service at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, discusses a novel treatment approach that combines potent hormone therapy with metastasis-directed stereotactic body radiation therapy to treat metastatic prostate cancer. Learn more at the UCLA Health Newsroom

Additional Coverage:  Medical Xpress, The ASCO Post


March 12, 2024
Dr. Calais on controversies in the treatment of patients with prostate cancerDr. Jeremie Calais, assistant professor of nuclear medicine and theranostics in the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center, provides expert commentary to OncLive.


March 11, 2024
Higher prostate cancer rates seen in black men, but advanced cases similar to white menDr. Amar Kishan, assistant professor and chief of genitourinary oncology service at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, provides expert commentary to MDEdge.


March 7, 2024
Unfold AI demonstrates utility for prostate cancer treatment planning in real-world case – Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA, provides expert commentary to Urology Times